[HTML][HTML] Neutralizing monoclonal antibodies for treatment of COVID-19
PC Taylor, AC Adams, MM Hufford… - Nature Reviews …, 2021 - nature.com
Several neutralizing monoclonal antibodies (mAbs) to severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) have been developed and are now under evaluation in clinical …
coronavirus 2 (SARS-CoV-2) have been developed and are now under evaluation in clinical …
Tackling COVID-19 with neutralizing monoclonal antibodies
Monoclonal antibodies (mAbs) have revolutionized the treatment of several human
diseases, including cancer and autoimmunity and inflammatory conditions, and represent a …
diseases, including cancer and autoimmunity and inflammatory conditions, and represent a …
Antibodies to combat viral infections: development strategies and progress
G Pantaleo, B Correia, C Fenwick, VS Joo… - Nature Reviews Drug …, 2022 - nature.com
Monoclonal antibodies (mAbs) are appealing as potential therapeutics and prophylactics for
viral infections owing to characteristics such as their high specificity and their ability to …
viral infections owing to characteristics such as their high specificity and their ability to …
Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model
Countermeasures to prevent and treat coronavirus disease 2019 (COVID-19) are a global
health priority. We enrolled a cohort of severe acute respiratory syndrome coronavirus 2 …
health priority. We enrolled a cohort of severe acute respiratory syndrome coronavirus 2 …
Infectious Diseases Society of America Guidelines on the treatment and management of patients with coronavirus disease 2019 (COVID-19)
Background There are many pharmacologic therapies that are being used or considered for
treatment of coronavirus disease 2019 (COVID-19). There is a need for frequently updated …
treatment of coronavirus disease 2019 (COVID-19). There is a need for frequently updated …
Prefusion F protein–based respiratory syncytial virus immunization in pregnancy
EAF Simões, KJ Center, ATN Tita… - … England Journal of …, 2022 - Mass Medical Soc
Background Respiratory syncytial virus (RSV), a major cause of illness and death in infants
worldwide, could be prevented by vaccination during pregnancy. The efficacy …
worldwide, could be prevented by vaccination during pregnancy. The efficacy …
Bronchiolitis
SR Dalziel, L Haskell, S O'Brien, ML Borland, AC Plint… - The Lancet, 2022 - thelancet.com
Viral bronchiolitis is the most common cause of admission to hospital for infants in high-
income countries. Respiratory syncytial virus accounts for 60–80% of bronchiolitis …
income countries. Respiratory syncytial virus accounts for 60–80% of bronchiolitis …
Single-dose nirsevimab for prevention of RSV in preterm infants
MP Griffin, Y Yuan, T Takas… - … England Journal of …, 2020 - Mass Medical Soc
Background Respiratory syncytial virus (RSV) is the most common cause of lower
respiratory tract infection in infants, and a need exists for prevention of RSV in healthy …
respiratory tract infection in infants, and a need exists for prevention of RSV in healthy …
A monoclonal antibody for malaria prevention
MR Gaudinski, NM Berkowitz, AH Idris… - … England Journal of …, 2021 - Mass Medical Soc
Background Additional interventions are needed to reduce the morbidity and mortality
caused by malaria. Methods We conducted a two-part, phase 1 clinical trial to assess the …
caused by malaria. Methods We conducted a two-part, phase 1 clinical trial to assess the …
Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants
D Wilkins, Y Yuan, Y Chang, AA Aksyuk, BS Núñez… - Nature Medicine, 2023 - nature.com
Nirsevimab is an extended half-life monoclonal antibody specific for the prefusion
conformation of the respiratory syncytial virus (RSV) F protein, which has been studied in …
conformation of the respiratory syncytial virus (RSV) F protein, which has been studied in …